why choose us

First received: July 13, 2023

Clinical Trial: Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

Study Status: Completed

Recruit Status: RECRUITING

Condition: Cutaneous T Cell Lymphoma

Study Type: INTERVENTIONAL


Official Title: A Phase II Study of Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

Brief Summary: This is an open-label, single-arm, multicenter, phase II study combining pembrolizumab and mogamulizumab in patients with advanced-stage, relapsed or refractory CTCL Each cycle will equal 6 weeks.Pembrolizumab will be administered on Day 1 of each cycle.Mogamulizumab will be administered on Day 1, 8, 15, and 22 of Cycle 1.For Cycle 2 and subsequent cycles, mogamulizumab will be administered on Day 1, 15 and 29 of each cycle.Subjects will undergo a response assessment prior to Cycle 3 and every 2 cycles…

Read more